Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][7] - The company has reported its half-year liquidity contract with Kepler Cheuvreux, detailing the resources available in its liquidity account as of December 31, 2024 [1][2] Financial Summary - As of December 31, 2024, the liquidity account had cash resources of €349,630.55 and 113,452 shares available [3] - The total number of buy-side executions for the semester was 1,281, with a traded volume of 215,444 shares amounting to €477,452.69 [3][6] - The total number of sell-side executions for the semester was 1,366, with a traded volume of 231,651 shares amounting to €538,913.35 [3][6] Clinical Development - Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial (NATiV3) for treating adult patients with MASH [8] - The company has a pipeline that includes odiparcil, which is currently under review for further development after a decision to focus on lanifibranor [9] - Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program [9] Company Overview - Inventiva has a scientific team of approximately 90 people with expertise in various fields, including biology, medicinal chemistry, and clinical development [10] - The company owns a library of around 240,000 pharmacologically relevant molecules, with about 60% being proprietary [10] - Inventiva is publicly listed on Euronext Paris and Nasdaq, indicating its presence in both European and American markets [11]
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux